Labiotech.eu

More News! 27 Jun 2019

German Biotech Will Target Parkinsonian Disorders with €12M Series A

Modag has developed a candidate drug targeting the neurodegenerative disease multiple system atrophy, which it plans to take to the clinic with €12M in Series A funds. Multiple system atrophy is a rare disorder, with similar symptoms to Parkinson’s disease, that is caused by breakdown of neurons in parts of the brain. The German biotech’s […]

June 27, 2019 - 2 minutesmins - By Helen Albert

More News! 26 Jun 2019

Carbios Raises €14.5M to Build Plant to Make 100% Recycled Plastic

The French bioplastics biotech Carbios has raised €14.5M through a placing of shares in order to fund the construction of a demonstration plant that will use enzymes to make 100% recycled plastics. Around 75% of the proceeds will fund the demonstration plant, which is due to be fully operational by the end of next year. […]

June 26, 2019 - 2 minutesmins - By Jonathan Smith

Spain biotech ecosystem Sanifit Mallorca

News and Trends 26 Jun 2019

Biotech Company in Mallorca Receives Spain’s Largest Biotech Fundraise

Mallorcan biotech Sanifit has broken the record for the largest private fundraise in the Spanish biotech sector raising a total of €72.2M. The fundraising consists of a €55.2M Series D round plus €17M in convertible bonds. The money will be used by Sanifit to fund an upcoming phase III trial of its lead drug candidate […]

June 26, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

erytech sqz biosciences cell therapy off the shelf

News and Trends 25 Jun 2019

US and French Biotech Partnership to Develop Off-the-Shelf Cell Therapies

The French biotech Erytech will license its red blood cell drug encapsulation technology to the US cell therapy company SQZ Biotechnologies for up to €50M. The partners plan to develop off-the-shelf cell therapies combining Erytech’s red blood cell drug encapsulation with SQZ Biotechnologies’ technology, which engineers immune cells to attack or protect specific disease targets. […]

June 25, 2019 - 2 minutesmins - By Jonathan Smith

nash liver fibrosis genfit terns pharmaceuticals organ

News and Trends 25 Jun 2019

Genfit’s NASH Drug to Be Developed in China in Deal Worth up to €200M

The US-Chinese company Terns Pharmaceuticals will develop and commercialize Genfit’s phase III drug elafibranor for the chronic liver disease NASH in China. As part of the deal, Genfit will receive a €31M ($35M) upfront fee and up to €170M ($193M) in developmental milestone payments. The two companies will also collaborate on other development programs for […]

June 25, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 25 Jun 2019

Update: Fund for Late-Stage European Biotechs Closes Final Round With €120M

Update (25/06/2019): The Luxembourg-based investor Vesalius Biocapital III has completed the final closing of a €120M fund to boost late-stage life science companies. Around 10-15 companies will receive investments from the fund, including specialists in drug development, med-tech, and diagnostics. Three companies have become beneficiaries so far, including the Finnish women’s health drug company Forendo […]

June 25, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

heart disease cardiovascular disease cholesterol zora biosciences

News and Trends 24 Jun 2019

Diagnostic Test Beats ‘Bad’ Cholesterol at Predicting Heart Attacks

A study run by the Finnish diagnostics biotech Zora Biosciences has found two biomarkers that are better at predicting heart attacks and deaths in patients with coronary heart disease than the current gold standard — measuring ‘bad’ cholesterol in the blood. To assess the risk of death or heart attacks in people with coronary […]

June 24, 2019 - 2 minutesmins - By Jonathan Smith

fecal transplant maat pharma fda enterobiotix

News and Trends 21 Jun 2019

Will US Fecal Transplant Death Impact European Biotech?

The death of a US patient from complications after a fecal transplant last week could have a major impact on microbiome research in Europe. The microbiome is a field with big potential for treating disease by targeting imbalances in the patient’s gut flora, such as by giving patients the stool bacteria of a healthy person […]

June 21, 2019 - 2 minutesmins - By Jonathan Smith

atelerix cell therapy newcastle freeze encapsulation

News and Trends 21 Jun 2019

This Biotech Transports Cell Therapies Without Needing a Freezer

The biotech Atelerix, based in Newcastle, UK, can transport cell therapies between different locations with less cost and risk than current methods by encapsulating the cells in a specialized gel. Mission: To eliminate the need for costly cold storage in the cell transport process by preserving cells in a gel. This could save further costs […]

June 21, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 20 Jun 2019

Spider Silk Could Improve Organoids for Drug Development

The Stockholm-based organoids company BioLamina has teamed up with the recombinant spider silk Stockholm startup Spiber Technologies to develop organoids that are more accurate tissue models than those used currently. Organoids are gaining popularity as a drug testing tool due to their capacity for modeling human tissue in 3D, which is more representative than 2D […]

June 20, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 19 Jun 2019

Scientists Grow Head and Neck Cancer Organoids to Personalize Chemotherapy

A team of Dutch researchers has developed the first 3D organoids from patients’ head and neck cancer cells that can be kept alive for a long time, giving physicians a model to test which cancer treatments are the most effective for each patient. Head and neck cancer is an aggressive disease that often requires harsh […]

June 19, 2019 - 3 minutesmins - By Jonathan Smith

ovarian cancer astrazeneca merck lynparza dna repair

News and Trends 19 Jun 2019

EU Gives Lynparza Green Light as First-Line Ovarian Cancer Treatment

The DNA damage repair drug olaparib (Lynparza), developed by AstraZeneca and Merck, has been approved by the EU as a first-line treatment preventing the return of ovarian cancer after initial chemotherapy. The drug has already been approved by the EU and the FDA as a maintenance treatment for relapsed ovarian cancer, and as a therapy […]

June 19, 2019 - 3 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

German Biotech Will Target Parkinsonian Disorders with €12M Series A

Carbios Raises €14.5M to Build Plant to Make 100% Recycled Plastic

Biotech Company in Mallorca Receives Spain’s Largest Biotech Fundraise

US and French Biotech Partnership to Develop Off-the-Shelf Cell Therapies

Genfit’s NASH Drug to Be Developed in China in Deal Worth up to €200M

Update: Fund for Late-Stage European Biotechs Closes Final Round With €120M

Diagnostic Test Beats ‘Bad’ Cholesterol at Predicting Heart Attacks

Will US Fecal Transplant Death Impact European Biotech?

This Biotech Transports Cell Therapies Without Needing a Freezer

Spider Silk Could Improve Organoids for Drug Development

Scientists Grow Head and Neck Cancer Organoids to Personalize Chemotherapy

EU Gives Lynparza Green Light as First-Line Ovarian Cancer Treatment

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!